中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (6): 465-470.doi: 10.35541/cjd.20210885
中华医学会皮肤性病学分会特应性皮炎研究中心 中华医学会皮肤性病学分会儿童学组
收稿日期:2021-12-06
修回日期:2022-05-10
发布日期:2022-06-02
通讯作者:
张建中；马琳
E-mail:rmzjz@126.com; bch_maleen@aliyun.com
Working Group for Atopic Dermatitis, Chinese Society of Dermatology; Working Group for Children′s Diseases, Chinese Society of Dermatology
Received:2021-12-06
Revised:2022-05-10
Published:2022-06-02
Contact:
Zhang Jianzhong; Ma Lin
E-mail:rmzjz@126.com; bch_maleen@aliyun.com
摘要： 【摘要】 特应性皮炎是一种常见的慢性炎症性皮肤病，以湿疹样皮疹和剧烈瘙痒为主要表现，可严重影响患者生活质量。中重度特应性皮炎往往需要系统治疗，传统的系统治疗对部分患者效果不佳或不能耐受。近年来，生物制剂开始用于临床治疗特应性皮炎，其中白细胞介素4受体拮抗剂度普利尤单抗已经在我国上市。中华医学会皮肤性病学分会特应性皮炎研究中心、中华医学会皮肤性病学分会儿童学组组织本领域部分专家讨论度普利尤单抗在中重度特应性皮炎治疗中的应用，并形成共识，希望本共识能为我国皮肤科医生临床应用度普利尤单抗治疗特应性皮炎提供参考。
中华医学会皮肤性病学分会特应性皮炎研究中心 中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022,55(6):465-470. doi:10.35541/cjd.20210885
Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus[J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470.doi:10.35541/cjd.20210885
| ［1］ | Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey［J］. Allergy, 2018,73（6）:1284⁃1293. doi: 10.1111/all.13401. |
| ［2］ | 顾恒, 尤立平, 刘永生, 等. 我国10城市学龄前儿童特应性皮炎现况调查［J］. 中华皮肤科杂志, 2004,37（1）:29⁃31. doi: 10.3760/j.issn:0412⁃4030.2004.01.011. |
| ［3］ | Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in Chinese children aged 1⁃7 ys［J］. Sci Rep, 2016,6:29751. doi: 10.1038/srep29751. |
| ［4］ | Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis［J］. Clin Dermatol, 2018,36（5）:595⁃605. doi: 10.1016/j.clindermatol.2018.05.007. |
| ［5］ | Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies［J］. Allergol Int, 2017,66（3）:398⁃403. doi: 10.1016/j.alit.2016.12.002. |
| ［6］ | Dainichi T, Kitoh A, Otsuka A, et al. The epithelial immune microenvironment （EIME） in atopic dermatitis and psoriasis［J］. Nat Immunol, 2018,19（12）:1286⁃1298. doi: 10.1038/s41590⁃ 018⁃0256⁃2. |
| ［7］ | Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:239⁃250. doi: 10.1111/jdv.15973. |
| ［8］ | Davidson WF, Leung D, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: mechanisms and interventions"［J］. J Allergy Clin Immunol, 2019,143（3）:894⁃913. doi: 10.1016/j.jaci.2019.01.003. |
| ［9］ | Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,143（1）:26⁃35. doi: 10.1016/j.jaci.2018.11.015. |
| ［10］ | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000. |
| ［11］ | 吕婷, 王宏伟. 老年特应性皮炎的认识和管理［J］. 中国皮肤性病学杂志, 2019,33（8）:949⁃954. doi: 10.13735/j.cjdv.1001⁃7089.201810075. |
| ［12］ | Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systematic review and meta⁃analysis［J］. Curr Opin Allergy Clin Immunol, 2015,15（5）:453⁃460. doi: 10.1097/ACI. 0000000000000198. |
| ［13］ | Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2021,84（2）:471⁃478. doi: 10.1016/j.jaad.2020.02.055. |
| ［14］ | Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta⁃analysis［J］. Ann Allergy Asthma Immunol, 2021,127（1）:49⁃56.e1. doi: 10.1016/j.anai.2021.02.026. |
| ［15］ | Silverberg JI. Comorbidities and the impact of atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2019,123（2）:144⁃151. doi: 10.1016/j.anai.2019.04.020. |
| ［16］ | Xu YC, Wang JP, Zhu WJ, et al. Childhood atopic dermatitis as a precursor for developing attention deficit/hyperactivity disorder［J］. Int J Immunopathol Pharmacol, 2020,34:2058 73842096 2902. doi: 10.1177/2058738420962902. |
| ［17］ | Liu P, Zhao Y, Mu ZL, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis［J］. Chin Med J （Engl）, 2016,129（7）:757⁃762. doi: 10.4103/0366⁃6999.178960. |
| ［18］ | Cheng R, Zhang H, Zong W, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:542⁃548. doi: 10.1111/jdv.15979. |
| ［19］ | Leshem YA, Hajar T, Hanifin JM, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study［J］. Br J Dermatol, 2015,172（5）:1353⁃1357. doi: 10.1111/bjd.13662. |
| ［20］ | Silverberg JI, Lei D, Yousaf M, et al. Comparison of Patient⁃Oriented Eczema Measure and Patient⁃Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: a validation study［J］. Ann Allergy Asthma Immunol, 2020,125（1）:78⁃83. doi: 10.1016/j.anai.2020.03.006. |
| ［21］ | Silverberg JI, Margolis DJ, Boguniewicz M, et al. Validation of five patient⁃reported outcomes for atopic dermatitis severity in adults［J］. Br J Dermatol, 2020,182（1）:104⁃111. doi: 10.1111/bjd.18002. |
| ［22］ | Kido⁃Nakahara M, Yokote G, Yoshida M, et al. Atopic Dermatitis Control Tool （ADCT）: a useful tool for self⁃evaluation in patients with atopic dermatitis［J］. J Dermatol, 2021,48（12）:1951⁃1952. doi: 10.1111/1346⁃8138.16176. |
| ［23］ | US Food and Drug Administration. DUPIXENT （dupilumab） Prescribing Information［DB/OL］. ［2022⁃05⁃22］. https://www.regeneron.com/downloads/dupixent_fpi.pdf. |
| ［24］ | Lee JH, Kim JE, Park GH, et al. Consensus update for systemic treatment of atopic dermatitis［J］. Ann Dermatol, 2021,33（6）:497⁃514. doi: 10.5021/ad.2021.33.6.497. |
| ［25］ | Paller AS, Simpson EL, Siegfried EC, et al. Efficacy and safety of dupilumab in children aged ≥6 months to ＜6 years with moderate⁃to⁃severe atopic dermatitis［C/OL］//3rd Annual Revolutionizing Atopic Dermatits Conference （RAD 2021）, 2021［2022⁃05⁃12］. https://djbpnesxepydt.cloudfront.net/radv/December2021/690_Abstract_AD⁃1539⁃Part⁃B_Primary_Paller⁃et⁃al_1639409383487.pdf. |
| ［26］ | Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS［J］. J Am Acad Dermatol, 2020,82（6）:1328⁃1336. doi: 10.1016/j.jaad.2020.02.060. |
| ［27］ | Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open⁃label study of single⁃dose dupilumab in children aged 6 months to < 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:464⁃475. doi: 10.1111/jdv.16928. |
| ［28］ | Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis［J］. N Engl J Med, 2016,375（24）:2335⁃2348. doi: 10.1056/NEJMoa 1610020. |
| ［29］ | Zhao Y, Wu L, Lu Q, et al. The efficacy and safety of dupilumab in Chinese patients with moderate⁃to⁃severe atopic dermatitis: a randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2022,186（4）:633⁃641. doi: 10.1111/bjd.20690. |
| ［30］ | Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial［J］. JAMA Dermatol, 2020,156（1）:44⁃56. doi: 10.1001/jamadermatol.2019.3336. |
| ［31］ | Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate⁃to⁃severe atopic dermatitis: results from a phase Ⅱa open⁃label trial and subsequent phase Ⅲ open⁃label extension［J］. Br J Dermatol, 2020,182（1）:85⁃96. doi: 10.1111/bjd.18476. |
| ［32］ | Blauvelt A, de Bruin⁃Weller M, Gooderham M, et al. Long⁃term management of moderate⁃to⁃severe atopic dermatitis with dupilumab and concomitant topical corticosteroids （LIBERTY AD CHRONOS）: a 1⁃year, randomised, double⁃blinded, placebo⁃controlled, phase 3 trial［J］. Lancet, 2017,389（10086）:2287⁃2303. doi: 10.1016/S0140⁃6736（17）31191⁃1. |
| ［33］ | Li Y, Lu J, Chen R, et al. The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: a single⁃center retrospective study［J］. Dermatol Ther, 2022,35（5）:e15385. doi: 10.1111/dth.15385. |
| ［34］ | Gu C, Wu Y, Luo Y, et al. Real⁃world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single⁃centre, prospective, open⁃label study［J/OL］. J Eur Acad Dermatol Venereol, 2022. （2022⁃03⁃28）［2022⁃05⁃23］. https://onlinelibrary.wiley.com/doi/10.1111/jdv.18109. doi: 10.1111/jdv.18109. |
| ［35］ | Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double⁃blinded, placebo⁃controlled phase 3 trial［J］. J Am Acad Dermatol, 2020,83（5）:1282⁃1293. doi: 10.1016/j.jaad.2020.06. 054. |
| ［36］ | 田晶, 梁源, 申春平, 等. 儿童中重度特应性皮炎首次皮下注射度普利尤单抗短期疗效和安全性分析［J］. 中华皮肤科杂志, 2022,55（4）:299⁃303. doi: 10.35541/cjd.20210734. |
| ［37］ | Lobo Y, Lee RC, Spelman L. Atopic dermatitis treated safely with dupilumab during pregnancy: a case report and review of the literature［J］. Case Rep Dermatol, 2021,13（2）:248⁃256. doi: 10.1159/000515246. |
| ［38］ | Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real⁃life study［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:958⁃964. doi: 10.1111/jdv.17094. |
| ［39］ | Patruno C, Fabbrocini G, Longo G, et al. Effectiveness and safety of long⁃term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real⁃life observational study［J］. Am J Clin Dermatol, 2021,22（4）:581⁃586. doi: 10. 1007/s40257⁃021⁃00597⁃5. |
| ［40］ | Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta⁃analysis of randomized controlled trials［J］. J Am Acad Dermatol, 2018,78（1）:62⁃69.e1. doi: 10.1016/j.jaad.2017.09.052. |
| ［41］ | Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis［J］. Am J Clin Dermatol, 2019,20（3）:443⁃456. doi: 10.1007/s40257⁃019⁃00445⁃7. |
| ［42］ | Sklover L, Nielson C, De Benedetto A. The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: case report［J］. Dermatol Ther, 2019,32（6）:e13144. doi: 10.1111/dth.13144. |
| ［43］ | Ludriksone L, Elsner P, Malessa C, et al. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report［J］. J Dtsch Dermatol Ges, 2020,18（7）:740⁃742. doi: 10.1111/ddg.14074. |
| ［44］ | Avallone G, Trunfio M, Giura MT, et al. Dupilumab in HIV⁃positive patients with atopic dermatitis: a long⁃term follow⁃up patient and a literature review［J］. Dermatol Online J, 2021,27（8）. doi: 10.5070/D327854709. |
| ［45］ | Ly K, Smith MP, Thibodeaux Q, et al. Dupilumab in patients with chronic hepatitis B on concomitant entecavir［J］. JAAD Case Rep, 2019,5（7）:624⁃626. doi: 10.1016/j.jdcr.2019.05.007. |
| ［46］ | Nakanishi M, Oota E, Tomita Y, et al. A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab［J］. J Dermatolog Treat, 2019,30（7）:674⁃676. doi: 10.1080/09546634.2019.1568379. |
| ［47］ | Goto H, Moriki M, Sano Y, et al. Successful preoperative intervention of dupilumab in high⁃risk surgery in a patient with severe atopic dermatitis［J］. J Dermatol, 2020,47（2）:e50⁃e51. doi: 10.1111/1346⁃8138.15187. |
| ［48］ | Fowler E, Rosen J, Lev⁃Tov H, et al. Two cancer patients receiving dupilumab for treatment of atopic dermatitis［J］. Acta Derm Venereol, 2019,99（10）:899⁃900. doi: 10.2340/00015555⁃3201. |
| ［49］ | Qiu Y, Ali K, Lou H, et al. Successful treatment of atopic dermatitis with dupilumab in a patient with non⁃Hodgkin′s lymphoma［J］. Acta Derm Venereol, 2022,102:adv00625. doi: 10.2340/actadv.v101.224. |
| ［50］ | Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion［J］. Expert Opin Drug Saf, 2021,20（9）:997⁃1004. doi: 10.1080/14740338.2021. 1939673. |
| ［51］ | Miyashiro D, Vivarelli AG, Gonçalves F, et al. Progression of mycosis fungoides after treatment with dupilumab: a case report［J］. Dermatol Ther, 2020,33（6）:e13880. doi: 10.1111/dth.13880. |
| ［52］ | Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T⁃cell lymphoma after dupilumab: case review of 7 patients［J］. J Am Acad Dermatol， 2020,83（1）:197⁃199. doi: 10.1016/j.jaad.2020.03.050. |
| ［53］ | Poyner E, Bacon CM, Osborne W, et al. Dupilumab unmasking cutaneous T⁃cell lymphoma: report of a fatal case［J］. Clin Exp Dermatol, 2022,47（5）:974⁃976. doi: 10.1111/ced.15079. |
| ［54］ | Nettis E, Fabbrocini G, Ortoncelli M, et al. Long⁃term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients［J］. Br J Dermatol, 2021,184（3）:561⁃563. doi: 10.1111/bjd.19577. |
| ［55］ | Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2020,156（2）:131⁃143. doi: 10.1001/jamadermatol.2019.3617. |
| ［56］ | Halling AS, Loft N, Silverberg JI, et al. Real⁃world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2021,84（1）:139⁃147. doi: 10.1016/j.jaad.2020.08.051. |
| ［57］ | Akinlade B, Guttman⁃Yassky E, de Bruin⁃Weller M, et al. Conjunctivitis in dupilumab clinical trials［J］. Br J Dermatol, 2019,181（3）:459⁃473. doi: 10.1111/bjd.17869. |
| ［58］ | Ou Z, Chen C, Chen A, et al. Adverse events of Dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a meta⁃analysis［J］. Int Immunopharmacol, 2018,54:303⁃310. doi: 10.1016/j.intimp.2017.11.031. |
| ［59］ | Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate⁃to⁃severe atopic dermatitis: results from three phase Ⅲ trials （LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS）［J］. Br J Dermatol, 2020,182（5）:1120⁃1135. doi: 10.1111/bjd.18434. |
| ［60］ | Zirwas MJ, Wulff K, Beckman K. Lifitegrast add⁃on treatment for dupilumab⁃induced ocular surface disease （DIOSD）: a novel case report［J］. JAAD Case Rep, 2019,5（1）:34⁃36. doi: 10.1016/j.jdcr.2018.10.016. |
| ［61］ | Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab［J］. Am J Ophthalmol Case Rep, 2017,7:120⁃122. doi: 10.1016/j.ajoc.2017.06.017. |
| ［62］ | Aszodi N, Thurau S, Seegräber M, et al. Management of dupilumab⁃associated conjunctivitis in atopic dermatitis［J］. J Dtsch Dermatol Ges, 2019,17（5）:488⁃491. doi: 10.1111/ddg. 13809. |
| ［63］ | Agnihotri G, Shi K, Lio PA. A clinician′s guide to the recognition and management of dupilumab⁃associated conjunctivitis［J］. Drugs R D, 2019,19（4）:311⁃318. doi: 10. 1007/s40268⁃019⁃00288⁃x. |
| ［64］ | Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis［J］. J Am Acad Dermatol, 2022,86（3）:628⁃636. doi: 10.1016/j.jaad.2021.06.017. |
| ［65］ | Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine⁃induced immunity: a randomized, placebo⁃controlled trial in adults with moderate⁃to⁃severe atopic dermatitis［J］. J Am Acad Dermatol, 2019,80（1）:158⁃167.e1. doi: 10.1016/j.jaad.2018.07.048. |
| ［66］ | Martinez⁃Cabriales SA, Kirchhof MG, Constantinescu CM, et al. Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: a consensus meeting, 2020［J］. Am J Clin Dermatol, 2021,22（4）:443⁃455. doi: 10.1007/s40257⁃021⁃00607⁃6. |
| [1] | 吴淑辉 朱明芳 魏露 张曦 覃秋艳 王畅. 石榴皮多酚对大鼠耳廓痤疮模型mTOR/HIF-1α/RORγt信号通路的影响[J]. 中华皮肤科杂志, 2022, 55(6): 511-516. |
| [2] | 赵柳琦 陈妍 陈丹阳 樊碧娆 王瑞 尚盼盼 陈喜雪 朱学骏 王明悦. 【开放获取】度普利尤单抗治疗大疱性类天疱疮21例的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(6): 480-485. |
| [3] | 黄馨 陈筱昀 李亚萍 梁兴堃 张桂英 周英 湛意 罗帅寒天 廖洁月 肖嵘 龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493. |
| [4] | 张寒梅 冯素英. 天疱疮合并单纯疱疹病毒感染的研究进展[J]. 中华皮肤科杂志, 2022, 55(6): 545-548. |
| [5] | 陆晓云 张曾云鸥 肖风丽. 上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用[J]. 中华皮肤科杂志, 2022, 55(6): 548-551. |
| [6] | 温广东 冒丹丹 张原媛 窦沅青 赵培 吴晨雨 张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 55(6): 508-510. |
| [7] | 徐西光 卢彬 孙建方. 表现为特应性皮炎样皮损的X连锁无丙种球蛋白血症1例[J]. 中华皮肤科杂志, 2022, 55(6): 536-537. |
| [8] | 孙晓丽 李邻峰. 肥大细胞在变应性接触性皮炎发病中的作用进展[J]. 中华皮肤科杂志, 2022, 55(5): 449-451. |
| [9] | 胡烨蓓 宋秀祖. 氨甲环酸治疗黄褐斑的研究进展[J]. 中华皮肤科杂志, 2022, 55(5): 460-462. |
| [10] | 张晓 陈凤鸣 柳琳 罗莉 郭金 高天文 石琼. Ⅰ期皮肤黑素瘤163例临床病理特征及预后分析[J]. 中华皮肤科杂志, 2022, 55(5): 389-394. |
| [11] | 申晨 陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445. |
| [12] | 王傲 姚煦. 特应性皮炎瘙痒机制的研究进展[J]. 中华皮肤科杂志, 2022, 55(4): 357-361. |
| [13] | 张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767. |
| [14] | 覃诗纯 李梦杰 陆晓云 肖风丽. 特应性皮炎的转录组学研究进展[J]. 中华皮肤科杂志, 2022, 55(4): 365-369. |
| [15] | 罗帅寒天 龙海 陆前进, . 2021年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2022, 55(4): 369-372. |
|
